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Summary
Background Severe mental illness is associated with increased morbidity and mortality. The elevated risk of blood-
borne viruses (BBVs) in people with severe mental illness is of concern, but the full extent of this problem is unclear. 
We aimed to determine the prevalence of and risk factors for BBVs in people with severe mental illness.
Methods In this nationwide, population-based, cross-sectional study, we estimated the point prevalence of HIV, 
hepatitis B (HBV), and hepatitis C (HCV) in people with severe mental illness, including the total adult (≥18 years) 
Swedish population. We defined severe mental illness as a clinical diagnosis of schizophrenia, schizoaffective 
disorder, bipolar disorder, or other psychotic illness according to the Swedish version of the International Statistical 
Classification of Diseases version 8, 9, or 10. We used multivariable logistic regression to determine the odds of BBVs 
in individuals with severe mental illness, relative to the general population, and to identify independent risk factors 
(age, sex, immigration status, socioeconomic status, education, and substance misuse) for BBV infection. We also did 
a sensitivity analysis excluding BBV diagnoses made before the introduction of the Register for Infection Disease 
Control (1997).
Findings Of 6 815 931 adults in Sweden, 97 797 (1·43%) individuals had a diagnosis of severe mental illness. 
Prevalence of BBVs was elevated in people with severe mental illness, of which 230 (0·24%) had HIV, 518 (0·53%) 
had HBV, and 4476 (4·58%) had HCV. After accounting for sociodemographic characteristics, the odds of HIV 
were 2·57 (95% CI 2·25–2·94, p<0·0001) times higher in people with severe mental illness than in the general 
population, whereas the odds of HBV were 2·29 (2·09–2·51, p<0·0001) times higher and the odds of 
HCV were 6·18 (5·98–6·39, p<0·0001) times higher. Substance misuse contributed most to the increased risk of 
BBV: after adjustment, odds ratios were 1·61 (1·40–1·85, p<0·0001) for HIV, 1·28 (1·16–1·41, p<0·0001) for HBV, 
and 1·72 (1·67–1·78, p<0·0001) for HCV.
Interpretation Our results highlight the need to address the issue of higher prevalence of BBVs in people with severe 
mental illness and identify interventions preventing infection. Targeting of comorbid substance misuse would have 
particular effect on reduction of BBV prevalence in this population.
Funding Medical Research Council and Swedish Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Severe mental illness is commonly defined as a mental 
disorder that is persistent and disabling in nature, such 
as schizophrenia, schizoaffective disorder, bipolar 
disorder, and other psychoses.1 Increased mortality 
rates of 2–3 times the general population are well 
documented among people with severe mental illness, 
and translate into a reduction in life expectancy of up to 
20 years.2 Approximately 60% of this excess in mortality 
has been attributed to poor physical health.2 Although 
much attention has been focused on addressing 
cardiovascular, respiratory, and cancer health 
inequalities, infectious diseases have been largely 
neglected in mental health research and policy.3 This 
situation is problematic as meta-analytic evidence 
suggests blood-borne virus (BBV) prevalence is elevated 
amongst individuals with severe mental illness.3 In 
North America, the pooled prevalence of BBVs in 
populations with severe mental illness is estimated to 
be as high as 6% for HIV, 2·2% for hepatitis B 
virus (HBV), and 17·4% for hepatitis C virus (HCV).3 
Therefore, HIV and HCV are ten times, and HBV 
around five times, more common in people with 
severe mental illness than in the general population.4 
Although lower, similar patterns are evident in 
people with severe mental illness in European 
countries (Germany, Belgium, Spain, Greece, Italy), 
with combined prevalence estimates of 1·9% for HIV, 
2·7% for HBV, and 4·9% for HCV.3 However, the true 
scale of the problem is unclear, because previous 
studies have used small, unrepresentative convenience 
samples recruited from treatment settings.3 As far as 
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we are aware, no population-based studies have been 
done of BBV prevalence in severe mental illness, and 
no studies have examined prevalence in northern 
European countries.3 Additionally, literature on risk 
factors for BBV in individuals with severe mental 
illness is limited, but high prevalence of substance 
misuse has been identified as a particular concern in 
this group.5
To address this gap, we did a total population study of 
Sweden to establish the prevalence of HIV, HBV, and 
HCV in people with severe mental illness. Furthermore, 
we identified risk of infection relative to the general 
population, and specific sociodemographic and clinical 
risk factors for BBV infection in people with severe 
mental illness.
Methods
Study design and population
We did a nationwide, population-based, cross-sectional 
study using longitudinal data from Swedish national 
registers held by Statistics Sweden and the Swedish 
National Board of Health and Welfare. Registers were 
linked using the unique personal identification number 
assigned to each Swedish citizen at birth or to 
immigrants on arrival in Sweden who have been granted 
at least 12 months’ residency; it is not dependent on 
having a Swedish address. The only people missing 
from the registers would have been recent immigrants 
with unconfirmed status. Personal identification 
numbers are recorded in all contacts with health-care, 
social, and administrative services (both private and 
Research in context
Evidence before this study
We searched PubMed, PsychINFO, and Embase for studies 
examining the association between severe mental illness and 
blood-borne viruses (BBVs) published in English from 
Jan 1, 1980, to Aug 1, 2016. We used the search terms “severe 
mental illness”, “serious mental illness”, “schizophrenia”, 
“schizoaffective disorder”, “bipolar disorder”, “psychosis”, 
“blood-borne viruses”, “human immunodeficiency virus”, 
“HIV”, “Hepatitis B”, “HBV”, “Hepatitis C”, and “HCV”. 
Additionally, we did a hand search of electronic journals. 
We identified a recent meta-analysis, which reviewed the 
literature on the prevalence of HIV, hepatitis B (HBV), and 
hepatitis C (HCV) in people with severe mental illness until 
Jan 1, 2015. We identified no additional studies. Evidence 
suggests infection with BBVs in people with severe mental 
illness is higher than in the general population in places 
where the prevalence of BBVs is low, and on par with the 
general population in places where prevalence of BBVs is 
high. In North America, the pooled prevalence of BBVs in 
people with severe mental illness is as high as 6·0% (range 
0·24–22·9) for HIV, 2·2% (0·78–4) for HBV, and 17·4% 
(2·7–38) for HCV. In the limited number of European studies, 
the pooled prevalence rates were 1·9% (range 0·5–5·1) for 
HIV, 2·7% (2–4·8) for HBV, and 4·9% (0·7–10·7) for HCV. 
However, the available studies are of moderate to low quality, 
with small sample sizes, and are likely to overestimate the 
prevalence owing to use of unrepresentative convenience 
samples from treatment settings. Furthermore, there is a 
paucity of research in northern European countries.
Added value of this study
To the best of our knowledge, this study is the first to 
investigate the prevalence of and risk factors for HIV, HBV, 
and HCV infection in people with severe mental illness 
(schizophrenia, bipolar disorder, schizoaffective disorder, and 
non-organic psychosis) using a nationwide, population-based 
sample, and the first study to investigate the relationship 
between BBV and severe mental illness prevalence in 
northern Europe. The study is based on the entire adult 
Swedish population, comprised of 6 815 931 people. This 
sample size allowed us to generate more precise and 
representative estimates compared with previous studies and 
augmented the sparse research available on the topic. 
Compared with previous European studies of patients with 
severe mental illness, prevalence of HIV and HBV was lower, 
but HCV was similar. All BBVs were increased in individuals 
with severe mental illness compared with the general 
population. Furthermore, we assessed the risk factors 
associated with this increase in prevalence of HIV, HBV, and 
HCV in people with severe mental illness. We found substance 
misuse history conveys the greatest risk in all BBV 
(approximately four times the risk of HIV and HBV, 
and 25 times the risk of HCV).
Implications of all the available evidence
Individuals with severe mental illness are at greater risk of 
infection with BBVs, which probably contributes to the excess 
of morbidity and mortality observed in this population. 
This problem has not been widely addressed. Effective drug 
treatment is available for both severe mental illness and BBV, 
but additional support might be required in this population to 
ensure treatment adherence and manage comorbidities. 
Management of sexual health and substance misuse in people 
with severe mental illness is needed to tackle the increased risk 
of infection. Facilitation of access to sexual health clinics for 
people with severe mental illness and targeted BBV screenings 
in mental health services might provide potential pathways to 
address this issue. However, given the substantial risk 
substance misuse poses for infection with BBVs in the severe 
mental illness population, helping people manage their 
substance misuse and implementing harm reduction 
strategies should be the major focus of any intervention. 
Future research should focus on identifying the most effective 
interventions to address the excess of HIV, HBV, and HCV 
infection in people with severe mental illness.
For Statistics Sweden see 
http://www.scb.se/en
For the Swedish National Board 
of Health and Welfare see 
http://www.socialstyrelsen.se/
english
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state). We compared the prevalence of BBV in those with 
severe mental illness and in the general population. We 
included all individuals aged 18 years or older who were 
alive on Dec 31, 2010. The study was approved by the 
research ethics committee at the Karolinska Institute, 
Stockholm, reference numbers 2010/1185-31/5 and 
2013/1118-32.
Diagnoses
Severe mental illness was defined as a clinical diagnosis of 
schizophrenia, schizoaffective disorder, bipolar disorder, 
or other psychotic illnesses (excluding any substance-
induced psychosis, but including diagnoses such as 
delusional disorder and unspecified psychosis) according 
to the Swedish version of the International Statistical 
Classification of Diseases (ICD) version 8, 9 or 10 
(appendix).6 Diagnoses could derive from either inpatient 
or outpatient records included in the National Patient 
Register. Inpatient records began in 1964 and outpatient 
records in 2001, with full population coverage (ie, everyone 
with a personal identification number) by 1973 and 2006, 
respectively. In cases of multiple previous diagnoses, the 
most recent was chosen, because we judged this diagnosis 
was likely to be most accurate, by accounting for the full 
clinical history. The quality of Swedish registers has 
previously been validated for severe mental illness.7
BBV status was defined as having a diagnosis of HIV, 
HBV, or HCV according to ICD-8, ICD-9, or ICD-10 
(appendix).6 BBV status was identified via linkage to the 
National Patient Register and the Register for Infection 
Disease Control (complete from 1997). Sweden has 
mandatory reporting of all HIV,8 HBV,9 and HCV cases10 
to the Swedish Institute for Infectious Disease Control 
and therefore all individuals diagnosed with BBV in 
Sweden were included in the study.
Potential risk factors
Age, sex, ethnicity, socioeconomic status, education, 
and substance misuse have been identified as potential 
explanations for the association between BBV and 
severe mental illness in previous literature.11 We 
retrieved information regarding the age and sex of 
participants via the Total Population Register. Owing 
to insufficient available data on ethnicity, we used 
immigration status as a proxy, identifying immigration 
status via the Total Population Register. In line 
with previous Swedish register studies,12 we classified 
individuals as Swedish born or having immigrated into 
Sweden. We defined socioeconomic status as the 
disposable income for each individual in 2010, generated 
from the total family income, including any salary, 
benefits, and pensions. We categorised socioeconomic 
status by creating quintiles of the disposable income 
of the total Swedish population (<958, 958–1335, 
1336–1812, 1813–2505, and >2505 in hundreds of 
Swedish kronor). We categorised education into three 
levels: fewer than 10 years, 10–12 years, and more than 
12 years or having attended university. We retrieved 
socioeconomic status and education information from 
the Longitudinal Integration Database for Health 
Insurance and Labour Market Studies (see Statistics 
Sweden). We defined a history of substance misuse as 
having a clinical diagnosis of substance misuse in 
the inpatient or outpatient National Patient Register, or 
receiving a prescription for any opiate replacement 
therapy, which was identified via the Prescribed Drug 
Register (which began in 2005; see the Swedish National 
Board of Health and Welfare). We considered substance 
misuse as potentially being on the causal pathway 
between severe mental illness and BBV.
Statistical analysis
We calculated the point prevalence of HIV, HBV, and 
HCV in the general population and in those with a 
severe mental illness diagnosis on Dec 31, 2010, with 
additional subdivision by severe mental illness diagnosis. 
To examine the increased risk of having BBV with a 
severe mental illness diagnosis, relative to the general 
population, we used logistic regression specifying 
severe mental illness status as the predictor and BBV 
status as the outcome. Multivariable logistic regression 
models were fitted to assess the effect of covariates on 
these univariable associations. Firstly, we controlled 
for age and sex, and then we additionally controlled 
for immigration status, socioeconomic status, and 
education. Finally, we controlled for history of substance 
misuse in addition to all previous covariates. We did a 
sensitivity analysis excluding BBV diagnoses made 
before the introduction of the Register for Infection 
Disease Control (1997).
To identify potential risk factors for individual BBVs, 
multivariable logistic regression models were fitted for 
the total population with severe mental illness subtype as 
an interaction term. We specified BBVs as the outcome 
with age, sex, immigration status, socioeconomic status, 
education, and substance misuse as predictors. We 
assessed effect modification using likelihood ratio tests. 
We used Stata (version 14) for all data management and 
analyses.
Role of the funding source
Funding was provided by the Medical Research Council 
(MR/K021362/1) and the Swedish Research Council 
(523-2010-1052). Neither had any role in the study design; 
data collection, analysis, or interpretation; in the writing 
of the report; or in the decision to submit the Article for 
publication. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The total adult Swedish population was 6 815 931, of 
which 97 797 (1·43%) individuals had a diagnosis of 
severe mental illness: 21 232 (0·31%) were diagnosed 
See Online for appendix
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with schizophrenia, 6180 (0·09%) with schizoaffective 
disorder, 34 576 (0·51%) with bipolar disorder, and 
35 809 (0·53%) with other psychosis (table 1). Education 
history was missing for 131 816 (1·94%) individuals, but 
no other variables had missing data.
Of the general population, 0·09% had an HIV 
diagnosis. The prevalence of HIV in those with severe 
mental illness was 0·24%, but differed by diagnostic 
subgroup (table 2). The odds of HIV infection in those 
with severe mental illness was nearly three times 
higher than in the general population (table 3). An 
increase in odds was present for all severe mental 
illness diagnoses. This pattern remained after 
adjustment for age, sex, immigration status, socio-
economic status, and education, as well as after 
additional adjustment for substance misuse (table 3). 
Results were of a similar magnitude when pre-1997 
diagnosis of HIV was excluded (odds ratio [OR] 1·54, 
95% CI 1·32–1·80, p<0·0001).
In the general population, being male was a risk factor 
for HIV, similarly in those with bipolar disorder and 
other psychosis diagnoses (table 4). However, in 
individuals with a schizophrenia diagnosis, being male 
reduced the odds. Having a history of substance misuse 
increased the odds of HIV infection in those with and 
without severe mental illness. Being Swedish born was 
more protective in the general population than in those 
with severe mental illness (table 4).
In the general population, 0·21% of individuals were 
infected with HBV, with a higher prevalence among 
Total population 
(N=6 815 931)
Severe mental illness 
(n=97 797)
Severe mental illness 
and HIV (n=230)
Severe mental illness 
and HBV (n=518)
Severe mental illness 
and HCV (n=4476)
Age (years) 46 (32–60) 52 (41–63) 48 (42–55) 44 (35–50) 48 (40–55)
Female 3 377 433 (49·55%) 50 800 (51·94%) 89 (38·70%) 188 (36·29%) 1532 (34·23%)
Male 3 438 498 (50·45%) 46 997 (48·06%) 141 (61·30%) 330 (63·71%) 2944 (65·77%)
Swedish born 5 631 926 (82·63%) 80 192 (82·00%) 153 (66·52%) 289 (55·79%) 3751 (83·80%)
History of substance misuse 269 029 (3·95%) 26688341 (26·93%) 142 (61·74%) 341 (65·83%) 4038 (90·21%)
Quintiles of socioeconomic status
1 (lowest) 1 287 197 (18·89%) 20 768 (21·24%) 68 (29·57%) 201 (38·80%) 1346 (30·07%)
2 1 340 562 (19·67%) 38 434 (39·30%) 83 (36·09%) 217 (41·89%) 2131 (47·61%)
3 1 381 293 (20·27%) 20 621 (21·09%) 55 (23·91%) 78 (15·06%) 738 (16·49%)
4 1 400 902 (20·55%) 10 587 (10·83%) 16 (6·96%) 13 (2·51%) 175 (3·91%)
5 (highest) 1 405 976 (20·63%) 7387 (7·55%) 8 (3·48%) 9 (1·74%) 86 (1·92%)
Education*
<10 years 1 309 214/6 684 115 
(19·59%)
28 799/96 096 
(29·97%)
87/221 (39·37%) 262/499 (52·51%) 2092/4390 (47·65%)
10–12 years 3 113 825/6 684 115 
(46·59%)
44 086/96 096 
(45·88%)
96/221 (43·44%) 192/499 (38·48%) 2008/4390 (45·74%)
>12 years or university 2 261 076/6 684 115 
(33·83%)
23 211/96 096 
(24·15%)
38/221 (17·19%) 45/499 (9·02%) 290/4390 (6·61%)
Data are n (%) or median (IQR). HBV=hepatitis B virus. HCV=hepatitis C virus. *Education data was missing for 131 816 (1·94%) individuals. 
Table 1: Clinical and demographic characteristics
Single infection Dual co-infection Triple co-infection
HIV HBV HCV HIV and HBV HIV and HCV HBV and HCV HIV, HBV, and HCV
General population 
(N=6 815 931)
5909 (0·09%) 14 783 (0·22%) 41 600 (0·61%) 272 (<0·01%) 762 (0·01%) 2545 (0·04%) 56 (<0·01%)
Any severe mental illness 
(n=97 797)
230 (0·24%) 518 (0·53%) 4476 (4·58%) 13 (0·01%) 106 (0·11%) 271 (0·28%) 7 (0·01%)
Schizophrenia (n=21 232) 44 (0·21%) 112 (0·53%) 1194 (5·62%) ·· 25 (0·12%) 55 (0·26%) ··
Schizoaffective disorder 
(n=6180)
12 (0·19%) 35 (0·57%) 199 (3·22%) ·· 6 (0·10%) 16 (0·26%) ··
Bipolar disorder (n=34 576) 45 (0·13%) 91 (0·26%) 958 (2·77%) ·· 11 (0·03%) 48 (0·14%) ··
Other psychosis (n=35 809) 129 (0·36%) 280 (0·78%) 2125 (5·93%) 11 (0·03%) 64 (0·18%) 152 (0·42%) 5 (0·01%)
Data are n (%). HBV=hepatitis B virus. HCV=hepatitis C virus. ··=fewer than five individuals (reporting of which is not permitted by Swedish data sharing rules).
Table 2: Prevalence of single, dual, and triple infections with blood-borne viruses
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individuals with severe mental illness (table 2). The 
unadjusted odds of HBV infection were more than 
two times higher for individuals with severe mental illness 
than in the general population (table 3). After adjustment 
for age, sex, immigration status, socioeconomic status, 
and education, the odds of HBV infection in individuals 
with severe mental illness remained elevated. This 
increase in odds was present for all severe mental illness 
diagnoses (table 3). The odds of HBV infection also 
remained elevated after additional adjustment for 
substance misuse. The OR increased when pre-1997 
diagnoses were excluded (OR 1·43, 95% CI 1·32–1·56, 
p<0·0001).
In both the severe mental illness population and 
individuals without severe mental illness, being male, 
non-Swedish born, having a history of substance 
misuse, and being of lower socioeconomic status 
increased the risk of having HBV (table 4). Odds of 
HBV infection fell with increasing age in individuals 
without severe mental illness, and in those with 
schizophrenia, bipolar, or other psychosis. As with HIV, 
being Swedish born was more protective for those 
without severe mental illness than for those with severe 
mental illness diagnoses.
HCV was the most common BBV, with a prevalence 
of 0·61% in the general population (table 2). 
Furthermore, HCV showed the greatest increase in 
prevalence in those with severe mental illness 
diagnoses. Prevalence was also higher than in the 
general population for each individual severe mental 
illness diagnosis (table 2). The odds of HCV infection 
were more than eight times higher in individuals 
with severe mental illness than in those without, 
with all diagnoses showing a significant increase in 
odds (table 3). This pattern persisted after adjustment 
for age, sex, immigration, socioeconomic status, and 
education, and adjustment for substance misuse in 
addition to all previous confounders (table 3). Results 
were of a similar magnitude when we excluded HBV 
diagnoses before 1997 (OR 1·64, 95% CI 1·58–1·71, 
p<0·0001).
Being male increased the odds of HCV diagnosis in 
individuals without severe mental illness, or with 
schizophrenia, bipolar disorder, or other psychosis 
groups (table 4). Being older was associated with 
increased odds of HCV in the general population, but 
reduced odds of infection in those with schizophrenia, 
bipolar disorder, and other psychosis. Increased socio-
economic status and years in education reduced HCV 
risk universally. A substance misuse history dramatically 
elevated the odds of HCV (table 4).
Dual co-infections were rare in the general population 
(table 2). The prevalence of co-infection was higher in the 
severe mental illness population than in the general 
population. Triple co-infection was very rare in all 
populations (table 2).
Discussion
In this study of BBV and severe mental illness covering 
the entire adult population of Sweden, we found the 
prevalence of infection with HIV, HBV, and HCV in 
individuals with severe mental illness was considerably 
Unadjusted Model 1 Model 2 Model 3
HIV
Any severe mental illness 2·79 (2·44–3·18); p<0·0001 2·86 (2·51–3·26); p<0·0001 2·57 (2·25–2·94); p<0·0001 1·61 (1·40–1·85); p<0·0001
Schizophrenia 2·45 (1·82–3·04); p<0·0001 2·37 (1·76–3·20); p<0·0001 2·11 (1·57–2·85); p<0·0001 1·38 (1·03–1·87); p=0·033
Schizoaffective disorder 2·30 (1·30–4·05); p=0·0040 2·47 (1·40–4·36); p=0·0017 2·20 (1·25–3·89); p=0·0064 1·43 (0·81–2·53); p=0·22
Bipolar disorder 1·54 (1·15–2·07); p=0·0039 1·65 (1·23–2·21); p=0·00086 1·81 (1·34–2·43); p<0·0001 1·09 (0·81–1·47); p=0·57
Other psychosis 4·27 (3·59–5·09); p<0·0001 4·34 (3·64–5·16); p<0·0001 3·43 (2·86–4·11); p<0·0001 2·12 (1·76–2·55); p=0·00013
HBV
Any severe mental illness 2·50 (2·29–2·73); p<0·0001 2·81 (2·57–3·06); p<0·0001 2·29 (2·09–2·51); p<0·0001 1·28 (1·16–1·41); p<0·0001
Schizophrenia 2·49 (2·07–3·00); p<0·0001 2·83 (2·35–3·41); p<0·0001 1·99 (1·64–2·42); p<0·0001 1·17 (0·96–1·42); p=0·13
Schizoaffective disorder 2·67 (1·92–3·73); p<0·0001 3·10 (2·23–4·34); p<0·0001 2·42 (1·73–3·39); p<0·0001 1·43 (1·02–2·01); p=0·038
Bipolar disorder 1·24 (1·01–1·52); p=0·041 1·40 (1·14–1·72); p=0·0014 1·66 (1·34–2·04); p<0·0001 0·88 (0·72–1·09); p=0·24
Other psychosis 3·70 (3·29–4·17); p<0·0001 4·06 (3·61–4·58); p<0·0001 2·79 (2·47–3·15); p<0·0001 1·56 (1·37–1·76); p<0·0001
HCV
Any severe mental illness 8·63 (8·36–8·91); p<0·0001 8·62 (8·35–8·90); p<0·0001 6·18 (5·98–6·39); p<0·0001 1·72 (1·67–1·78); p<0·0001
Schizophrenia 10·72 (10·11–11·37); p<0·0001 9·84 (9·28–10·45); p<0·0001 5·81 (5·46–6·17); p<0·0001 2·02 (1·89–2·15); p<0·0001
Schizoaffective disorder 5·99 (5·20–6·99); p<0·0001 6·33 (5·49–7·30); p<0·0001 4·50 (3·90–5·19); p<0·0001 1·29 (1·11–1·49); p=0·0011
Bipolar disorder 5·13 (4·81–5·47); p<0·0001 5·38 (5·04–5·75); p<0·0001 4·54 (4·25–4·85); p<0·0001 1·08 (1·01–1·16); p=0·022
Other psychosis 11·35 (10·85–11·88); p<0·0001 11·28 (10·78–11·80); p<0·0001 8·11 (7·74–8·49); p<0·0001 2·19 (2·07–2·29); p<0·0001
Data are OR (95% CI); p value. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, immigration status, education, and socioeconomic status. Model 3 is 
adjusted for age, sex, immigration status, education, socioeconomic status, and substance misuse. HBV=hepatitis B virus. HCV=hepatitis C virus.
Table 3: Odds of infection with blood-borne viruses in people with severe mental illness compared with the general population
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higher than in the general population. This increase 
was not fully explained by differences in age, sex, 
immigration status, socioeconomic status, educational 
level, or substance misuse history. However, a history 
of substance misuse had the biggest effect on BBV 
risk. Apart from substance misuse, risk factors for BBV 
appear to act differentially across severe mental illness 
subtypes. In individuals without severe mental illness, 
being an immigrant into Sweden, being of lower 
socioeconomic status, and having reduced time in 
education all increase BBV risk, but we could not show 
this result consistently in severe mental illness 
subtypes.In particular, women with schizophrenia 
have increased risk of HIV compared with men (ie, OR 
for men of 0·54) whereas this is reversed in the general 
population
To our knowledge, this population-based study is the 
first to investigate the prevalence and risk factors for 
Without severe mental 
illness
Schizophrenia Schizoaffective 
disorder
Bipolar disorder Other psychoses p value*
Risk factor for HIV
Male sex† 1·68 (1·59–1·78) 0·54 (0·30–0·97) 0·97 (0·31–3·08) 1·83 (1·00–3·31) 1·60 (1·08–2·36) 0·0078
Age (years)‡ 1·00 (0·998–1·002) 0·986 (0·963–1·010) 0·958 (0·915–1·003) 0·994 (0·975–1·014) 0·998 (0·986–1·011) 0·27
Swedish born§ 0·18 (0·17–0·19) 0·47 (0·25–0·90) 0·71 (0·19–2·63) 0·39 (0·20–0·77) 0·48 (0·33–0·69) <0·0001
History of substance misuse¶ 3·96 (3·65–4·29) 4·11 (2·25–7·52) 6·02 (1·81–20·04) 3·25 (1·79–5·91) 4·25 (2·93–6·15) 0·90
Quintiles of socioeconomic status|| 0·13
2 0·94 (0·87–1·02) 0·67 (0·33–1·35) 0·44 (0·13–1·52) 0·66 (0·27–1·57 0·85 (0·55–1·33)
3 0·86 (0·79–0·94) 1·10 (0·47–2·59) 0·21 (0·02–1·82) 1·22 (0·53–2·78) 1·27 (0·79–2·03)
4 0·76 (0·70–0·83) 1·03 (0·23–4·57) 0·76 (0·70–0·83) 1·35 (0·53–3·42) 0·52 (0·22–1·24)
5 (highest) 0·93 (0·85–1·02) 0·93 (0·85–1·02) 2·12 (0·24–18·39) 0·69 (0·19–2·50) 0·62 (0·22–1·72)
Education** 0·65
10–12 years 0·90 (0·84–0·96) 1·07 (0·57–2·00) 1·50 (0·37–6·02) 0·90 (0·42–1·92) 0·83 (0·56–1·22)
>12 years or university 0·91 (0·85–0·98) 0·73 (0·24–2·14) 1·90 (0·38–9·46) 1·53 (0·71–3·30) 0·63 (0·35–1·11)
Risk factor for HBV
Male sex† 1·29 (1·24–1·34) 0·97 (0·63–1·49) 1·52 (0·77–3·00) 1·44 (0·95–2·19) 1·22 (0·94–1·58) 0·68
Age (years)‡ 0·984 (0·983–0·985) 0·978 (0·963–0·992) 0·982 (0·956–1·009) 0·979 (0·966–0·993) 0·971 (0·962–0·979) 0·039
Swedish born§ 0·07 (0·07–0·08) 0·23 (0·16–0·34) 0·14 (0·07–0·28) 0·30 (0·19–0·48) 0·37 (0·29–0·47) <0·0001
History of substance misuse¶ 4·82 (4·59–5·06) 5·30 (3·53–7·95) 4·52 (2·27–8·97) 5·98 (3·76–9·52) 5·21 (4·02–6·75) 0·84
Quintiles of socioeconomic status|| 0·011
2 0·92 (0·88–0·96) 0·68 (0·44–1·06) 1·34 (0·58–3·06) 1·24 (0·75–2·04) 0·78 (0·59–1·02)
3 0·75 (0·71–0·79) 0·99 (0·56–1·77) 1·00 (0·34–2·94) 0·68 (0·35–1·31) 0·61 (0·42–0·88)
4 0·63 (0·59–0·67) 0·63 (0·59–0·67) 0·63 (0·59–0·67) 0·29 (0·09–0·97) 0·35 (0·18–0·70)
5 (highest) 0·53 (0·50–0·57) 1·31 (0·30–5·57) 0·53 (0·50–0·57) 0·80 (0·30–2·09) 0·16 (0·04–0·66)
Education** 0·60
10–12 years 0·68 (0·65–0·70) 0·83 (0·55–1·24) 0·56 (0·27–1·16) 0·52 (0·33–0·81) 0·63 (0·49–0·82)
>12 years or university 0·52 (0·50–0·54) 0·55 (0·26–1·56) 0·31 (0·09–1·06) 0·34 (0·18–0·64) 0·37 (0·24–0·58)
Risk factor for HCV
Male sex† 1·50 (1·46–1·53) 1·31 (1·13–1·52) 1·03 (0·76–1·38) 1·18 (1·03–1·34) 1·40 (1·27–1·55) 0·0002
Age (years)‡ 1·009 (1·008–1·009) 0·995 (0·990–1·000) 1·003 (0·991–1·015) 0·995 (0·991–0·999) 0·996 (0·993–0·999) <0·0001
Swedish born§ 0·86 (0·84–0·89) 1·23 (1·03–1·46) 1·09 (0·74–1·60) 0·88 (0·72–1·08) 1·35 (1·19–1·53) <0·0001
History of substance misuse¶ 32·04 (31·34–32·76) 30·84 (25·39–37·46) 20·67 (13·61–31·38) 16·68 (13·78–20·20) 32·13 (27·30–37·81) <0·0001
Quintiles of socioeconomic status|| 0·12
2 0·83 (0·80–0·85) 0·76 (0·65–0·89) 0·79 (0·55–1·13) 0·84 (0·71–1·00) 0·75 (0·67–0·84)
3 0·57 (0·55–0·59) 0·60 (0·49–0·75) 0·61 (0·38–0·97) 0·59 (0·49–0·72) 0·53 (0·46–0·61)
4 0·45 (0·43–0·46) 0·20 (0·11–0·37) 0·20 (0·06–0·65) 0·34 (0·25–0·45) 0·38 (0·31–0·48)
5 (highest) 0·35 (0·34–0·37) 0·28 (0·12–0·65) 0·46 (0·11–1·97) 0·35 (0·25–0·49) 0·27 (0·19–0·37)
Education** 0·0006
10–12 years 0·82 (0·80–0·84) 0·70 (0·61–0·80) 0·92 (0·67–1·26) 0·71 (0·61–0·82) 0·87 (0·78–0·96)
>12 years or university 0·48 (0·47–0·50) 0·29 (0·21–0·41) 0·41 (0·23–0·74) 0·38 (0·30–0·47) 0·39 (0·32–0·47)
Data are OR (95% CI) or p values. Each analysis is controlled for all other risk factors in the table. HBV=hepatitis B virus. HCV=hepatitis C virus. *Test for effect modification. †Reference group: female sex. 
‡Per 1-year increase in age. §Reference group: non-Swedish born. ¶Reference group: no history of substance misuse. ||Reference group: lowest quintile of SES (1). **Reference group: <10 years of education.
Table 4: Associations between key characteristics and infection with blood-borne viruses
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BBVs in people with severe mental illness, and provides 
the first estimate of prevalence of BBVs in individuals 
with severe mental illness in Sweden, which has 
comprehensive health service coverage. The large, 
full-population sample allowed for precise and 
representative estimates. Furthermore, because HIV, 
HBV, and HCV are statutorily notifiable infections in 
Sweden and data quality has previously been validated 
for both BBVs and severe mental illness,7–10 we believe 
our findings represent as accurate and complete case 
recording as is possible in a routine setting, without 
mandatory testing. Some points should be considered 
in terms of the generalisability of these findings. The 
relatively high prevalence of HCV in the general 
population of Sweden has been reported in previous 
literature, and is thought to be related to high rates of 
recreational drug use during the 1960s and 1970s in 
Swedish-born individuals.10,13 Our study potentially 
overestimates HCV prevalence, because not all cases 
become chronic (viraemic rate ranges from 74% 
to 91%).13 However, our general population prevalence 
is consistent with a 2012 estimate of 0·56% for 
Sweden.13 The general population prevalence of BBVs 
in Sweden is similar to other northern European 
countries such as Denmark and the UK.13–16
Compared with previous literature, our prevalence 
estimates for both HIV and HBV in the severe mental 
illness population are lower than those of other European 
studies.3 Our estimate for HCV lies within the wide 
range found previously in Europe (0·7–10·7%).3 In most 
of these studies, BBV testing was done as part of routine 
care during inpatient treatment, whereas in our study 
individuals would only be tested when an opportunity to 
do so arose (ie, contact with a health professional). 
Individuals might not seek help for either severe mental 
illness or BBV diagnoses and so would not be in the 
registers, leading to a potential underestimation of 
prevalence. This situation might be particularly true for 
HCV, for which symptoms are mild and might go 
undiagnosed.17 We were unable to determine whether 
the opportunity to receive a BBV diagnosis is the same 
for individuals with severe mental illness and those 
without. However, given that individuals with severe 
mental illness receive less appropriate assessment and 
treatment for physical health problems than do the 
general population,18 this difference might also be 
reflected in assessment and treatment for BBVs. As 
such, our study potentially differentially underestimates 
the prevalence of BBVs in severe mental illness 
compared with the general population. Previous studies 
in the general population,19 and a limited number of 
studies of patients with severe mental illness,4,20 have 
identified male sex, substance misuse, lower 
socioeconomic status, reduced education, and non-white 
ethnicity as risk factors for BBVs. As far as we are aware, 
our study is the first to show different effects of risk 
factors by BBV and severe mental illness subgroups.
Our study has other potential limitations. The study 
design adopted does not allow us to make inferences 
about the temporality of the relationship between BBVs 
and severe mental illness. However, the primary aim 
was to estimate point prevalence and, as such, a cross-
sectional methodology was most appropriate. Also, 
given that most severe mental illness has an onset in 
early adulthood,21 most BBV infection was likely to be 
contemporaneous or later. Diagnosis of severe mental 
illness and BBV occurred at different times and was 
made based on different versions of the ICD. Therefore, 
potential misclassification exists within subgroups of 
severe mental illness, which we attempted to limit by 
using the most recent diagnosis code recorded in 
medical records. However, misclassification into the 
severe mental illness group versus the group without 
severe mental illness is unlikely. We were unable to 
ascertain whether particular symptoms or phases of 
illness conveyed particular risk (for example, manic 
states have been associated with increased risk of HIV 
acquisition22). Our measure of substance misuse 
(diagnosis or opiate replacement prescribing) might be 
imperfect and additional risk behaviours might explain 
increased BBV prevalence in severe mental illness 
relative to the general population. For example, we 
were unable to account for incarceration, homelessness, 
and risky sexual behaviours.19,20 Also, our binary 
immigration status variable might not capture the 
range of potential baseline risk associated with 
particular countries. As such, we recognise the 
potential for residual and unmeasured confounding in 
our study. Conversely, one could argue that many of 
the risk behaviours mediate, rather than confound, the 
relationship between severe mental illness and BBVs, 
and their inclusion in a regression model would result 
in overadjustment. All variables had complete data, 
apart from education, which had 1·94% missing 
values. Missing data below 5–10% should have little 
effect on statistical inference, so we did a complete-
case analysis.23 We found no evidence that missing data 
was related to either BBV or severe mental illness 
diagnosis, therefore this approach should be unbiased. 
Finally, despite the large sample size, our study 
might have been underpowered to examine some 
risk factors for less common severe mental illness 
diagnoses (eg, the effect of education on HIV risk in 
schizoaffective disorder).
This study has important implications for policy and 
practice. BBVs contribute to mortality in the general 
population, with HBV and HCV found to increase 
all-cause mortality by 2·3 times, and 5·8 times, 
respectively.24 Comorbidity of BBV infection and severe 
mental illness provides a worse prognosis for both 
conditions.25 As such, the increased prevalence of BBVs 
probably accounts for some of the excess mortality 
experienced by individuals with severe mental illness. 
Beyond this, BBV diagnosis is likely to contribute to 
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increased stigma26 and disability, and have negative 
effects on quality of life and illness course in those 
with severe mental illness.25 However, national 
guidelines for treatment of physical health problems in 
individuals with severe mental illness pay little 
attention to infectious disease risk and sexual health,27 
and consultations of sexual-history taking commonly 
fail to account for mental health problems.28 To 
effectively address the syndemic of severe mental 
illness, BBV, and substance misuse, integrated 
approaches to care that facilitate greater collaboration 
between mental health, sexual health, and substance 
misuse services are necessary. Potentially, testing for 
BBVs should become routinely available during contact 
with mental health and substance misuse services. 
Effective pharmaco therapy exists for both severe 
mental illness and BBVs, and treatments can be used 
together successfully with low risk of drug 
interactions.25 The clinical challenge is encouragement 
of treatment adherence and coordination of clinical 
services that are necessary to address the diverse 
psychiatric and medical problems that coexist in this 
population. Furthermore, prevention strategies should 
be adopted to reduce the risk of BBV infection among 
people with severe mental illness. Existing evidence is 
insufficient to appraise the effectiveness of sexual 
health risk reduction strategies, sexual health 
promotion, or interventions intended to change 
behavioural outcomes associated with BBV infection in 
severe mental illness.29 However, given the substantial 
risk substance misuse poses for the acquisition of 
BBVs, helping individuals with severe mental illness 
reduce harms associated with their substance use 
might be the most beneficial avenue to reduce infection 
rates. Additionally, such an intervention could affect 
other domains such as criminality, suicide, all-cause 
mortality, and general health and wellbeing.30 Evidence 
suggests that harm reduction strategies are effective at 
reducing BBV infection risk, with the strongest 
evidence for needle and syringe programmes and 
opioid substitution treatment.31 As such, greater 
commissioning and more widespread coverage of 
harm reduction strategies is necessary.
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